Aurinia Pharmaceuticals Inc (AUPH) Financials
AUPH Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 516.6 million | 157.2 million |
2023-12-31 | 548.1 million | 170.1 million |
2023-09-30 | 555.0 million | 163.1 million |
2023-06-30 | 548.9 million | 156.6 million |
AUPH Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | -18.6 million | ? |
2023-12-31 | 14.8 million | 11.8 million |
2023-09-30 | -13.2 million | 11.8 million |
2023-06-30 | -3.1 million | 12.3 million |
AUPH Net Income
No data available :(
AUPH Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 319.9 million | - | - |
2023-12-31 | 350.5 million | - | 97.6 million |
2023-09-30 | 337.9 million | - | 93.2 million |
2023-06-30 | 350.7 million | - | 101.2 million |
AUPH Shares Outstanding
AUPH Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 11999 | 5.6 million | - | - |
2023-12-31 | 49731 | 10.2 million | 50.1 million | - |
2023-09-30 | 105000 | 13.6 million | 47.8 million | - |
2023-06-30 | 227000 | 12.7 million | 47.1 million | - |
AUPH Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 50.3 million | 7.8 million |
2023-12-31 | 45.1 million | 5.4 million |
2023-09-30 | 54.5 million | 6.8 million |
2023-06-30 | 41.5 million | 1.6 million |
AUPH
Price: $5.10
52 week price:
Earnings Per Share: -0.54 USD
P/E Ratio: -15.29
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 2.2 million
Ebitda: -13.4 millionMarket Capitalization: 729.4 million